October 13, 2019
Pfizer’s abrocitinib met all endpoints in moderate to severe atopic dermatitis study
Pfizer has presented positive phase 3 data at the 28th Congress of the European Academy of Dermatology and Venereology for abrocitinib in moderate to severe atopic dermatitis, in which abrocitinib met all co-primary and secondary endpoints in JADE MONO-1 study.